ArticleJournal of ophthalmic inflammation and infection2023
Immunosuppressive therapy for Vogt-Koyanagi-Harada disease: a retrospective study and review of literature.
Article in Journal of ophthalmic inflammation and infection, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 19 citations in OpenAlex.
- Vogt-Koyanagi-Harada (VKH)-What Do We Know About the Disease, and Can We Recognize It?Diagnostics (Basel, Switzerland) · 2026Article
- Co-occurrence of Vogt-Koyanagi-Harada disease, diabetic retinopathy, and advanced chronic kidney disease: a case report.Frontiers in medicine · 2026Article
- Revising the role of cerebrospinal fluid pleocytosis as a diagnostic criterion in Vogt-Koyanagi-Harada disease.Eye (London, England) · 2025Article
- Steroid pulse therapy for VKH during pregnancy: a safe and effective option?Orphanet journal of rare diseases · 2025Review
- Predictive factors at initial visit for sunset glow fundus in Vogt-Koyanagi-Harada disease.Scientific reports · 2025Article
- A complicated Vogt-Koyanagi-Harada presenting with bilateral papillitis in a 5-year-old- case report.Journal of ophthalmic inflammation and infection · 2025Article
- [Vasculitis of the retina : Clinical aspects, diagnostics, management and treatment].Die Ophthalmologie · 2024Review
- Vogt-Koyanagi-Harada Syndrome from Dermatological Perspective: A Case Report.Indian dermatology online journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVogt-Koyanagi-Harada (VKH) disease is an idiopathic autoimmune disease which targets melanin-containing tissues such as the uvea, meninges, ear and skin. This typically presents in the eye with acute findings of granulomatous anterior uveitis, diffuse choroidal thickening, multiple focal areas of sub-retinal fluid and, in severe cases, optic nerve involvement with bullous serous retinal detachment can occur. Early initiation of treatment has been advocated to prevent progression to the chronic stage of the disease, which can result to a sunset glow fundus with devastatingly poor visual outcome. Treatment is usually initiated with corticosteroids followed by an early introduction of immunosuppressive treatment (IMT) to achieve immediate response after disease presentation, although the choice of IMT for VKH can vary. MAIN
findingsWe conducted a retrospective case-series to investigate the management trend of treating VKH over a 20-year period. Twenty-six patients were included and we found a shift from steroid monotherapy to combined IMT/low-dose steroid for the management of acute initial-onset of VKH in the last 10 years. Our average time from diagnosis to initiation of IMT was 2.1 months. 81% (21 of 26 patients) of our patients treated with combined IMT/steroid were able to achieve disease stability with significant good visual outcome at 24 months (Median VA SHORT
conclusionOur study found that patients with VKH who were treated with combined IMT/low-dose steroids achieved significantly better visual improvement at 24 months compared to steroid monotherapy. We frequently chose MMF and this appears to be well tolerated by our patients. Since its introduction, anti-TNF agents are increasingly becoming a popular choice of treatment for VKH as these have been shown to be safe and effective. However, more data is required to provide evidence that anti-TNF agents can be used as first-line treatment and as monotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.